Drug Trial Radar · NCT07487376
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
May 24, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- iBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
Conditions
- Overweight , Obesity
Interventions
IBIO-600Drug
IBIO-600 Subcutaneous injection
PlaceboDrug
Matching placebo; subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the safety and tolerability of a single dose of IBIO-600Time frame: From Day 1 through Day 252 (end of study).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Veritus Research
Bayswater, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.